| Literature DB >> 34884364 |
Albenita Fetahu1, Kaltrinë Rrustemi1, Michael Y Henein2,3,4, Besim Bytyçi5, Flamure Mehmeti6, Ibadete Bytyçi1,2,6, Lulzim Kamberi6.
Abstract
BACKGROUND AND AIM: Heart failure (HF) is a clinical syndrome associated with poor quality of life and prognosis, and premature mortality. The aim of this study was to assess the prevalence of depression and its risk factors in HF patients.Entities:
Keywords: HFpEF; HFrEF; depression scale; heart failure
Year: 2021 PMID: 34884364 PMCID: PMC8658509 DOI: 10.3390/jcm10235663
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Demographic and clinical data between HF patients with and without depression according to EF.
| Variable | HFrEF without Depression | HFrEF with Depression | HFpEF without Depression | HFpEF with Depression | ||
|---|---|---|---|---|---|---|
| Clinical indices | ||||||
| Age | 71.1 ± 11 | 68.2 ± 10 | 0.12 | 60.1 ± 12 | 68.2 ± 11 | 0.04 |
| Sex (female, %) | 41 (50.6) | 14 (60.8) | 0.03 | 18 (48.6) | 6 (60) | 0.01 |
| Smoking ( | 21 (25.9) | 5 (21.7) | 0.12 | 8 (21.6) | 2 (20) | 0.33 |
| BMI (m/kg2) | 26.3 ± 3.5 | 30.4 ± 2.9 | 0.04 | 27.9 ± 3.3 | 28.8 ± 4.4 | 0.13 |
| Underweight ( | 1 (1.23) | 0 (0) | 0.04 | 0 (0) | 0 (0) | 0.77 |
| Normal weight ( | 29 (35.8) | 11 (47.8) | 0.03 | 13 (43.2) | 4 (40) | 0.31 |
| Overweight ( | 29 (35.8) | 10 (43.5) | 0.04 | 15 (40.5) | 5 (50) | 0.003 |
| Obese ( | 21 (25.9) | 8 (34.7) | 0.02 | 10 (27.0) | 4 (40) | 0.002 |
| SBP (mmHg) | 106 ± 15 | 108 ± 14 | 0.63 | 111 ± 16 | 109 ± 14 | 0.70 |
| DBP (mmHg) | 78.1 ± 10 | 75 ± 13 | 0.32 | 83 ± 12 | 78 ± 16 | 0.52 |
| HR (beats/min) | 75 ± 10 | 73 ± 11 | 0.31 | 76 ± 13 | 74 ± 10 | 0.41 |
| NYHA class | 1.8 ± 1.0 | 2.9 ± 1.1 | 0.02 | 1.8 ± 0.9 | 2.9 ± 1.1 | 0.03 |
|
| ||||||
| AH ( | 56 (69.1) | 14 (60.9) | 0.08 | 24 (64.8) | 6 (60) | 0.10 |
| DM ( | 39 (48.1) | 13 (56.5) | 0.04 | 16 (43.1) | 5 (50) | 0.03 |
| Dyslipidemia | 23 (28.4) | 7 (30.4) | 0.51 | 10 (27.0) | 3 (30) | 0.61 |
| CHD ( | 41 (50.6) | 12 (52.2) | 0.21 | 14 (37.8) | 4 (40) | 0.33 |
| AF ( | 40 (51.8) | 15 (65.2) | 0.01 | 12 (32.4) | 4 (40) | 0.03 |
|
| ||||||
| Aspirin ( | 64 (79.1) | 18 (78.2) | 0.27 | 28 (75.7) | 8 (80) | 0.47 |
| ACE/ARBs ( | 67 (82.7) | 19 (82.6) | 0.55 | 30 (81.1) | 8 (80) | 0.35 |
| Diuretics ( | 58 (71.6) | 20 (86.9) | 0.001 | 22 (59.5) | 7 (70) | 0.02 |
| BB ( | 64 (79.1) | 19 (78.2) | 0.20 | 26 (70.3) | 7 (70) | 0.80 |
| CCB ( | 11 (13.6) | 3 (13.1) | 0.51 | 7 (18.9) | 2 (20) | 0.33 |
| Antiarrhythmic ( | 14 (17.3) | 5 (21.7) | 0.21 | 6 (16.2) | 2 (20) | 0.09 |
| Anticoagulation ( | 15 (18.5) | 7 (30.4) | 0.01 | 4 (10.8) | 1 (10) | 0.21 |
| Statins ( | 29 (29.6) | 7 (30.4) | 0.41 | 6 (16.2) | 1 (10) | 0.11 |
Body mass index (BMI), New York Heart Association (NYHA), arterial hypertension (AH), diabetes mellitus (DM), dyslipidemia, coronary heart disease (CHD), atrial fibrillation (AF); Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), angiotensin converting enzyme (ACE), angiotensin II receptors blockers (ARBs), beta clockers (BB), channel calcium blockers (CCB).
Laboratory data between HF patients with and without depression according to EF.
| Variable | HFrEF without Depression | HFrEF with Depression | HFpEF without Depression | HFpEF with Depression | ||
|---|---|---|---|---|---|---|
| Laboratory data | ||||||
| Glucose (mmol/L) | 5.9 ± 2.2 | 5.6 ± 1.2 | 0.02 | 5.6 ± 1.2 | 8.2 ± 3.2 | 0.02 |
| Urea (mmol/L) | 9.4 ± 5.6 | 16.1 ± 6.2 | 0.03 | 8.3 ± 4.2 | 14 ± 5.1 | 0.04 |
| Creatinine (umol/L) | 125 ± 11 | 165 ± 25 | 0.01 | 123 ± 11 | 145 ± 19 | 0.02 |
| Bilirubin (mg/dL) | 4.1 ± 1.1 | 5.5 ± 1.1 | 0.21 | 3.8 ± 1.3 | 4.9 ± 1.3 | 0.33 |
| ALT (U/L) | 30 ± 10 | 37 ± 11 | 0.32 | 34 ± 11 | 30 ± 10 | 0.18 |
| AST (U/L) | 33 ± 13 | 28 ± 10 | 0.51 | 30 ± 10 | 28 ± 14 | 0.31 |
| Albumin (g/L) | 30.3 ± 8.5 | 33 ± 9.1 | 0.24 | 31 ± 10 | 33 ± 9.6 | 0.32 |
| Protein (g/L) | 59 ± 11 | 61 ± 10 | 0.24 | 62 ± 10 | 64 ± 11 | 0.28 |
| Cholesterol (mmol/L) | 6.8± 3.2 | 6.2 ± 3.1 | 0.22 | 5.9 ± 3.5 | 6.8 ± 3.1 | 0.38 |
| Triglyceride (mmol/L) | 1.9 ± 0.8 | 2.1 ± 0.9 | 0.31 | 1.9 ± 0.8 | 2.2 ± 0.7 | 0.22 |
| WBC (103/mm3) | 9.4 ± 4.3 | 8.2 ± 4.6 | 0.29 | 9.2 ± 4.6 | 8.9 ± 3.4 | 0.37 |
| RBC (106/mm3) | 3.9 ± 1.2 | 4.4 ± 1.2 | 0.23 | 4.1 ± 1.2 | 4.7 ± 1.1 | 0.38 |
| Platelet (103/mm3 | 212± 23 | 217± 22 | 0.21 | 209± 21 | 215 ± 25 | 0.11 |
| Iron (umol/L) | 8.8 ± 2.8 | 13.1 ± 3.1 | 0.03 | 10.2 ± 3.1 | 9.9 ± 2.5 | 0.20 |
ALT: alanine aminotransferase; AST: aspartate aminotransferase; RBC: red blood cell; WBC: white blood cell.
Echocardiographic data between HF patients with and without depression according to EF.
| Variable | HFrEF without Depression | HFrEF with Depression | HFpEF without Depression | HFpEF with Depression | ||
|---|---|---|---|---|---|---|
| LV EDD (cm) | 5.7 ± 0.6 | 6.1 ± 0.7 | 0.10 | 5.1 ± 0.4 | 5.3 ± 0.6 | 0.33 |
| LV ESD (cm) | 3.5 ± 0.4 | 3.9 ± 0.4 | 0.21 | 3.6 ± 0.4 | 3.8 ± 0.5 | 0.23 |
| IVSd (cm) | 1.1 ± 0.1 | 1.0 ± 0.1 | 0.30 | 1.1 ± 0.1 | 1.2 ± 0.2 | 0.38 |
| LVPWd (cm) | 1.1 ± 0.2 | 1.1 ± 0.2 | 0.18 | 1.0 ± 0.1 | 1.1 ± 0.2 | 0.29 |
| LV EF (%) | 36 ± 2.8 | 34 ± 3.5 | 0.44 | 53 ± 2.9 | 55 ± 4.3 | 0.51 |
| LA diameter (cm) | 4.4 ± 4.4 | 4.6 ± 4.2 | 0.10 | 4.1 ± 3.9 | 4.2 ± 5.6 | 0.12 |
| RA diameter (cm) | 3.7 ± 1.4 | 3.8 ± 1.5 | 0.23 | 3.4 ± 1.6 | 3.5 ± 1.3 | 0.28 |
| RV diameter (cm) | 3.3 ± 1.2 | 3.5 ± 1.2 | 0.55 | 3.1 ± 1.1 | 3.2 ± 1.3 | 0.44 |
LV: left ventricle; EDD: end-diastolic dimension; ESD: end-systolic dimension; IVSd: inter-ventricular septum in diastole; PWd: parietal wall in diastole; EF: ejection fraction; LA: left atrium; RA: right atrium; RV: right ventricle.
Figure 1Correlation of demographic and clinical indices with depression; (A) correlation between New York Heart Association class (NYHA) class and depression; (B) correlation between Body mass index (BMI) and depression; (C) correlation between glycemic level and depression; (D) correlation between age and depression.
Predictors of depression in HF patients.
| Variable | Univariate Predictors | Multivariate Predictors | ||
|---|---|---|---|---|
|
| ||||
| Age | 1.231(1.051 to 2.401) | 0.03 | 1.362 (0.989 to 3.824) | 0.10 |
| Female gender | 2.735 (1.337 to 5.595) | 0.04 | 1.562 (0.809 to 4.024) | 0.22 |
| NYHA class > II | 2.035 (1.437 to 4.595) | 0.01 | 2.103 (1.389 to 4.700) | 0.01 |
| AH | 1.018 (0.509 to 3.903) | 0.61 | ||
| CHD | 1.141 (0.819 to 3.898) | 0.11 | ||
| BMI | 1.201 (0.909 to 4.108) | 0.10 | ||
| BMI ≥ 30 kg/m2 | 1.630 (1.207 to 3.803) | 0.01 | 1.890 (1.199 to 3.551) | 0.02 |
| Diabetes | 1.105 (0.895 to 3.796) | 0.09 | ||
| Glycemic level ≥ 8.5 mmol/L | 2.105 (1.405 to 3.796) | 0.001 | 2.802 (1.709 to 5.077) | 0.01 |
|
| ||||
| Age | 1.191(1.091 to 3.001) | 0.04 | 1.701 (0.913 to 3.119) | 0.11 |
| Female gender | 1.135 (0.937 to 2.095) | 0.10 | ||
| NYHA class > II | 1.830 (1.237 to 3.005) | 0.007 | 2.091 (1.613 to 4.009) | 0.01 |
| AH | 1.098 (0.811 to 3.211) | 0.22 | ||
| CHD | 1.109 (0.709 to 2.898) | 0.31 | ||
| BMI | 1.009 (0.801 to 3.701) | 0.18 | ||
| BMI ≥ 30kg/m2 | 1.890 (1.331 to 3.908) | 0.01 | 1.911 (1.401 to 4.018) | 0.03 |
| Diabetes | 1.205 (0.801 to 3.406) | 0.21 | ||
| Glycemic level ≥ 8.5 mmol/L | 1.961 (1.519 to 3.676) | 0.02 | 2.013 (1.519 to 4.101) | 0.01 |
|
| ||||
| Age | 1.161(1.007 to 1.399) | 0.02 | 1.301(0.977 to 3.019) | 0.08 |
| Female gender | 1.511 (1.193 to 3.121) | 0.04 | 1.591(1.110 to 3.029) | 0.04 |
| NYHA class > II | 1.311 (1.107 to 2.901) | 0.08 | ||
| AH | 1.011 (0.307 to 2.101) | 0.22 | ||
| CHD | 1.122 (0.530 to 2.537) | 0.61 | ||
| BMI | 1.129 (0.817 to 3.160) | 0.11 | ||
| BMI ≥ 30kg/m2 | 2.047 (1.108 to 3.397) | 0.02 | 1.926 (1.502 to 4.011) | 0.02 |
| Diabetes | 1.118 (0.909 to 2.915) | 0.17 | ||
| Glycemic level ≥ 8.5 mmol/L | 1.808 (1.015 to 3.541) | 0.03 | 1.703 (1.311 to 3101) | 0.03 |
AH: arterial hypertension; BMI: body mass index; CHD: coronary heart disease; DM: diabetes mellitus.